Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40JMN | ISIN: US17248W3034 | Ticker-Symbol:
NASDAQ
02.04.25
15:40 Uhr
4,090 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CINGULATE INC Chart 1 Jahr
5-Tage-Chart
CINGULATE INC 5-Tage-Chart

Aktuelle News zur CINGULATE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.03.Cingulate Inc. - 10-K, Annual Report4
26.03.Cingulate reports FY results4
26.03.Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved191In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date...
► Artikel lesen
26.03.Cingulate Inc. - 8-K, Current Report4
04.03.Cingulate Inc.: Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025126Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY...
► Artikel lesen
04.03.Cingulate Inc. - 8-K, Current Report-
03.02.Cingulate Inc. - 8-K, Current Report1
CINGULATE Aktie jetzt für 0€ handeln
24.01.Cingulate Inc. - 8-K, Current Report5
07.01.Cingulate Inc. - 8-K, Current Report5
23.12.24Cingulate Inc.: Cingulate Completes Financing Transaction for Net Proceeds of $5,000,0006
23.12.24Cingulate Inc. - 8-K, Current Report-
07.11.24Cingulate Inc.: Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market228KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology...
► Artikel lesen
07.11.24Cingulate Inc. - 10-Q, Quarterly Report14
07.11.24Cingulate Inc. - 8-K, Current Report-
15.10.24Cingulate Inc. - 8-K, Current Report3
08.10.24Cingulate Inc.: Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show7
07.10.24Cingulate sichert Finanzierung zur Verlängerung des Geschäftsbetriebs bis ins zweite Quartal 202514
07.10.24Cingulate secures funding to extend operations into Q2 20253
16.08.24Pre-market Movers: Cingulate, Greenland Technologies, Shimmick Corporation, Quantum BioPharma, CI&T951BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.20 A.M. ET).In the Green Cingulate Inc. (CING) is up over 89% at $9.08. Greenland...
► Artikel lesen
15.08.24Cingulate Inc.: Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD288KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1